CONVERGE-01 enrolled progressive PSMA-positive mCRPC after 1–6 prior Lu-177–PSMA cycles, with universal ARPI exposure and 80% prior taxane use in the ASCO cohort. Fractionated CONV01-α on days 1 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results